Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-20
2007-02-20
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100
Reexamination Certificate
active
10669474
ABSTRACT:
A DNA vaccine for the treatment of prostate cancer, comprising a plasmid vector comprising a nucleotide sequence encoding prostatic acid phosphatase (PAP) operably linked to a transcription regulatory element, wherein upon administration to a mammal a cytotoxic immune reaction against cells expressing PAP is induced. In preferred embodiment, the PAP encoded is a xenoantigen highly homologous to the autoantigen PAP of the mammal. Also disclosed are methods for inducing prostatitis, or inducing immune reaction to PAP, or treating prostate cancer in a mammal, using the DNA vaccine and pharmaceutical compositions comprising the vaccine. Preferably, xenoantigen vaccination is followed by boosting with autoantigen PAP from the same animal species as the mammal being treated.
REFERENCES:
patent: 5925362 (1999-07-01), Spitler et al.
patent: 6328969 (2001-12-01), Houghton et al.
Verma et al., Gene therapy-promises, problems and prospects. (1997) Nature. 389:239-242.
Orkin et al., Report and Reccommendations of the Panel to assess the NIH invextment in Research on Gene Therapy (1998) 1-41.
Marshall., Gene Therapy's Growing Pains (1995) Science 269:1050-1055.
Rosenberg et al. (2003) Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen. 14:709-714.
McCluskie et al. (1999) Route and method of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5:287-300.
Hu et al. (1998) Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T cell Response from a Type 2 to a Type 1 Cytokine Profile. J. Immunol. 161:3033-3041.
Acsadi G. Jiao SS. Jani A. Duke D. Williams P. Chong W. Wolff JA. Direct gene transfer and expression into rat Heart in vivo. [Journal Article]New Biologist. 3(1):71-81, Jan. 1991.
Boyer JD. Cohen AD. Vogt S. Schumann K. Nath B. Ahn L. Lacy K. Bagarazzi ML. Higgins TJ. Baine Y. Ciccarelli RB. Ginsberg RS. MacGregor RR. Weiner DB. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. [Clinical Trial. Clinical Trial, Phase I, Journal Article]Journal of Infectious Diseases. 181(2): 476-83, Feb. 2000.
Budker V. Zhang G. Knechtle S. Wolff JA. Naked DNA delivered intraportally expresses efficiently in hepatocytes. [Journal Article]Gene Therapy. 3(7):593-8, Jul. 1996.
Budker V. Gurevich V. Hagstrom JE. Bortzov F. Wolff JA. pH-sensitive, cationic liposomes: a new synthetic virus-like vector. [Journal Article]Nature Biotechnology. 14(6):760-4, Jun. 1996.
Budker V. Zhang G. Danko I. Williams P. Wolff J. The efficient expression of intravascularly delivered DNA in rat muscle. [Journal Article]Gene Therapy. 5(2):272-6, Feb.1998.
Burch PA. Breen JK. Buckner JC. Gastineau DA. Kaur JA. Laus RL. Padley DJ. Peshwa MV. Pitot HC. Richardson RL. Smits BJ. Sopapan P. Strang G. Valone FH. Vuk-Pavlovic S. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. [Clinical Trial. Clinical Trial, Phase I. Journal Article]Clinical Cancer Research. 6(6):2175-82, Jun. 2000.
Cadeddu JA. Partin AW. Epstein JI. Walsh PC. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. [Journal Article]Urology. 50(2):251-5, Aug. 1997.
Chen Y. Webster RG. Woodland DL. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. [Journal Article]Journal of Immunology. 160(5):2425-32, Mar. 1, 1998.
Cho HJ. Takabayashi K. Cheng PM. Nguyen MD. Corr M. Tuck S. Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism.[comment]. [Journal Article]Nature Biotechnology. 18(5):509-14, May 2000.
Danko I. Fritz JD. Jiao S. Hogan K. Latendresse JS. Wolff JA. Pharmacological enhancement of in vivo foreign gene expression in muscle. [Journal Article]Gene Therapy. 1(2):114-21, Mar. 1994.
Davis HL. Whalen RG. Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. [Journal Article]Human Gene Therapy. 4(2):151-9, Apr. 1993.
Fong L. Ruegg CL. Brockstedt D. Engleman EG. Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. [Journal Article]Journal of Immunology. 159(7):3113-7, Oct. 1, 1997.
Fong L. Brockstedt D. Benike C. Breen JK. Strang G. Ruegg CL. Engleman EG. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. [Clinical Trial. Clinical Trial, Phase I. Journal Article]Journal of Immunology. 167(12):7150-6, Dec. 15, 2001.
Guinan P. Ray P. Shaw M. Immunotherapy of prostate cancer: a review. [Review] [57 refs ] [Clinical Trial. Journal Article. Review]Prostate. 5(2):221-30, 1984.
Hartmann G. Weeratna RD. Ballas ZK. Payette P. Blackwell S. Suparto I. Rasmussen WL. Waldschmidt M. Sajuthi D. Purcell RH. Davis HL. Krieg AM. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. [Journal Article]Journal of Immunology. 164(3):1617-24, Feb. 1, 2000.
Irvine KR. Restifo NP. The next wave of recombinant and synthetic anticancer vaccines. [Review] [121 refs] [Journal Article. Review. Review, Tutorial]Seminars in Cancer Biology. 6(6):337-47, Dec. 1995.
Iwasaki A. Torres CA. Ohashi PS. Robinson HL. Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. [Journal Article]Journal of Immunology. 159(1):11-4, Jul. 1, 1997.
Lebowitz MS. O'Herrin SM. Hamad AR. Fahmy T. Marguet D. Barnes NC. Pardoll D. Bieler JG. Schnech JP. Soluble, high-affinity dimers T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. [Journal Article]Cellular Immunology. 192(2):175-84, Mar. 15, 1999.
Lee Ah. Suh YS. Sung. JH. Yang SH. Sung YC. Comparison of various expression plasmids for the induction of immune response by DNA immunization. [Journal Article]Molecules&Cells.7(4):495-501, Aug. 31, 1997.
Mahi-Brown CA. McGuinness RP. Moran F. The cellular immune response to immunization with zona pellucida antigens. [Journal Article]Journal of Reproductive Immunology. 21(1):29-46, Jan. 1992.
Mahi-Brown CA. Primate response to immunization with a homologous zona pellucida peptide. [Journal Article]Journal of Reproduction&Fertility—Supplement. 50:165-74, 1996.
Manthorpe M. Comefert-Jensen F. Hartikka J. Felgner J. Rundell A. Margalith M. Dwarki V. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. [Journal Article]Human Gene Therapy. 4(4):419-31, Aug. 1993.
McNeel DG. Schiffman K. Disis ML. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. [Clinical Trial. Clinical Trial, Phase I. Journal Article]Blood. 93(8):2653-9, Apr. 15, 1999.
McNeel DG. Nguyen LD. Storer BE. Vessella R. Lange PH. Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. [Journal Article]Journal of Urology. 164(5):1825-9, Nov. 2000.
McNeel DG. Disis ML. Tumor vaccines for the management of prostate cancer. [Review] [63 refs] [Journal Article. Review. Review, Tutorial]Archivum Immunologiae et Therapiae Experimentalis. 48(2):85-93, 2000.
McNeel DG. Nguyen LD. Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. [Journal Article]Cancer Research. 61(13):5161-7, Jul. 1, 2001.
McNeel DG. Nguyen LD. Ellis WJ. Higano CS. Lange PH. Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patient
Falk Anne-Marie
Lieto Louis D.
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Methods and compositions for treating prostate cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating prostate cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating prostate cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3813856